Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients

Thrombosis Research

Volumn 125, Issue 3, 2010, Pages 220-223

  Rondina, Matthew T ^a   Wheeler, Michelle ^b   Rodgers, George M ^a   Draper, Leslie ^b   Pendleton, Robert C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Low molecular weight heparin; Medically Ill; Obesity; Pharmacokinetics; Prophylaxis; Venous Thromboembolism

Indexed keywords

ENOXAPARIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MORBID OBESITY; PRIORITY JOURNAL; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; BODY MASS INDEX; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OBESITY, MORBID; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 76949088444     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.02.003     Document Type: Article

References (24)

1. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341 (1999) 793-800
2. Leizorovicz A., Cohen A.T., Turpie A.G., Olsson C.G., Vaitkus P.T., and Goldhaber S.Z. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 (2004) 874-879
3. Spyropoulos A.C. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest 128 (2005) 958-969
4. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39 (2000) 215-231
5. Ford E.S., and Mokdad A.H. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab 93 (2008) S1-8
6. Duplaga B.A., Rivers C.W., and Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21 (2001) 218-234
7. Kovacs M.J., Weir K., MacKinnon K., Keeney M., Brien W.F., and Cruickshank M.K. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res 91 (1998) 137-142
8. Matzsch T., Bergqvist D., Hedner U., and Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 57 (1987) 97-101
9. Vitoux J.F., Aiach M., Roncato M., and Fiessinger J.N. Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight?. Thromb Haemost 59 (1988) 120
10. Frederiksen S.G., Hedenbro J.L., and Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 90 (2003) 547-548
11. Clagett G.P., Anderson Jr. F.A., Geerts W., Heit J.A., Knudson M., Lieberman J.R., et al. Prevention of venous thromboembolism. Chest 114 (1998) 531S-560S
12. Rocha A.T., de Vasconcellos A.G., da Luz Neto E.R., Araujo D.M., Alves E.S., and Lopes A.A. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obes Surg 16 (2006) 1645-1655
13. Sanderink G.J., Le Liboux A., Jariwala N., Harding N., Ozoux M.L., Shukla U., et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72 (2002) 308-318
14. Bazinet A., Almanric K., Brunet C., Turcotte I., Martineau J., Caron S., et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 116 (2005) 41-50
15. Wilson S.J., Wilbur K., Burton E., and Anderson D.R. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism. Haemostasis 31 (2001) 42-48
16. Hainer J.W., Barrett J.S., Assaid C.A., Fossler M.J., Cox D.S., Leathers T., et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 87 (2002) 817-823
17. Samama M.M., C V, and L C. Relation between weight, obesity, and frequency of deep vein thrombosis after enoxaparin in orthopedic surgery [abstr]. Thromb Haemost 73 (1995) 977
18. Hamad G.G., and Choban P.S. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 15 (2005) 1368-1374
19. Rowan B.O., Kuhl D.A., Lee M.D., Tichansky D.S., and Madan A.K. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 18 (2008) 162-166
20. Crowther M., and Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 13 (2007) 409-413
21. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 26 Suppl 2 (1996) 24-38
22. Forestieri P., Quarto G., De Caterina M., Cuocolo A., Pilone V., Formato A., et al. Prophylaxis of thromboembolism in bariatric surgery with parnaparin. Obes Surg 17 (2007) 1558-1562
23. Hirsh J., Bauer K.A., Donati M.B., Gould M., Samama M.M., and Weitz J.I. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 141S-159S
24. Geerts W., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., and Colwell C.W. Prevention of venous thromboembolism. Chest 133 (2008) 381S-453S